Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efruxifermin in NASH/MASH and NAFLD/MASLD
NCT06161571Phase 3Active, not recruiting
- Sponsor
- Akero Therapeutics
- Start
- Nov 2023
- Primary completion
- Mar 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 13
01
Overview
A Phase 3 trial of efruxifermin in Nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), sponsored by Akero Therapeutics. Started Nov 2023; status: active, not recruiting.
02
Drugs
efruxifermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06161571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161571.